Advanced Magnesium Complex®
Maximum magnesium benefits from four bioavailable forms
- The most advanced magnesium supplement available
- Contains four bioavailable forms of magnesium, each with its own unique benefits
- Enhances energy production, mood and sleep
- Supports muscle function, bone health, and heart health
- Supports DNA
- Optimizes vitamin D status
Magnesium is required for over 300 different biochemical reactions in the body. Advanced Magnesium Complex® is a highly bioavailable formula that combines four sources of magnesium into one comprehensive supplement to ensure the body’s magnesium needs are met. This formula includes Magnesium Aspartate, Magnesium Ascorbate, Magnesium Malate and Magnesium Glycinate. They are most easily metabolized by various systems in the body, and each form provides more benefits than just magnesium alone.
Magnesium is critical for the energy producing processes in the body–because magnesium binds with ATP (adenosine triphosphate) to create and utilize the energy that we use in our bodies. Included are equal parts of malate and aspartate ions to support the malate/aspartate shuttle, an important metabolic process involved with energy production in the body. Decreased magnesium levels have been linked with decreased vitamin C levels, which is why magnesium ascorbate is part of this formula. Magnesium glycinate is included as the primary source of magnesium, as it is the gentlest on the digestive tract and won’t cause diarrhea.
AOR’s Advanced Magnesium Complex® provides a comprehensive magnesium formula which contains four of the most absorbable, effective and well-tolerated forms of magnesium, ensuring adequate absorption and usage by the body, and allowing for variations in individual body chemistry and requirements. It also provides useful salt or chelate forms whose benefits extend beyond those of magnesium alone, without the digestive problems caused by magnesium oxide.
Advanced Magnesium Complex® provides four sources of magnesium and helps the body to metabolize carbohydrates, proteins and fats, supports tissue and connective tissue formation and helps in the development and maintenance of cartilage, bones, teeth and gums. Advanced Magnesium Complex® also helps in wound healing, maintenance of proper muscle function and is an antioxidant for the maintenance of good health.
AOR™ guarantees that all ingredients have been declared on the label. Contains no wheat, gluten, corn, peanuts, sesame seeds, sulphites, mustard, soy, dairy, eggs or any animal by-product.
Take one to three capsules daily with/without food, or as directed by a qualified health care practitioner.
- Cardiovascular health
- Healthy muscle function
- Supports nerve function
The information and product descriptions appearing on this website are for information purposes only, and are not intended to provide or replace medical advice to individuals from a qualified health care professional. Consult with your physician if you have any health concerns, and before initiating any new diet, exercise, supplement, or other lifestyle changes.
*Provides 480 mg glycine, 50 mg aspartate, 50 mg malate.
Non-medicinal Ingredients: sodium stearyl fumarate, and microcrystalline cellulose. Capsule: hypromellose.
The role of magnesium in cardiovascular health cannot be understated. In this meta-analysis, published in 2006, the effect of magnesium supplementation as a treatment for primary hypertension in adults was evaluated. The inclusion criteria for this analysis were: i) randomized, controlled trials; ii) treatment and follow up lasting over eight weeks; iii) participants over 18 years old with raised systolic blood pressure (SBP), over 140 mmHg or diastolic blood pressure (DBP), over 85 mmHg and iv), iv) reports of SBP and DBP at the end of the study. Two reviewers independently abstracted data and assessed trial quality. Disagreements were resolved by discussion or a third reviewer. Random effects meta-analyses and sensitivity analyses were conducted. 12 randomized, with 545 participants were included in the analysis.
The results from all studies included showed that magnesium supplementation led to a significant reduction in DBP, but not a significant decrease in SBP, showing the benefits of magnesium on blood pressure and cardiovascular outcomes.
Another more recent meta-analysis, published in 2012, assessed the effect of magnesium supplementation on blood pressure. 22 randomized, controlled trials, with 1173 participants and duration of 3-24 weeks were included in the analysis. The results show a clinically significant reduction in blood pressure with magnesium supplementation. Additionally, this effect was dose-dependent.
The ARIC (Atherosclerosis Risk in Communities) study, published in 2010, evaluated the relationship between serum magnesium levels and the risk of sudden cardiac death (SCD) in a cohort of 14,322 patients, in the age range of 45- to 64-year-olds, over a 2 year period between 1987 and 1989. After an average of 12 years of follow-up, we observed 264 cases of SCD, as determined by physician review of all suspected cases.
The results show that individuals with a higher serum magnesium level were associated with an almost 40% lower risk of SCD, suggesting that magnesium levels may be an important predictor of SCD.
A systematic review and meta-analysis of prospective studies investigated the prospective associations between circulating and dietary magnesium with the incidence of cardiovascular disease (CVD), including fatal and nonfatal ischemic heart disease. Sixteen studies, comprising 313,014 individuals (11,995 CVD, 7534 IHD, and 2686 fatal IHD events) were included in the analysis. The results show that circulating magnesium was associated with a 30% lower risk of CVD and trends towards lower risks of IHD. At least 200 mg/day of magnesium supplementation was associated with a 22% lower risk of IHD, and an inverse relation between 250 mg magnesium per day and fatal IHD was observed.
These studies were designed as a dose-response meta-analysis of prospective studies, with trial sequential analysis to evaluate the available evidence for the relationship between magnesium supplementation and the risk of strokes. After review, the first study included seven prospective studies, with 6477 cases of strokes and 241,378 total participants for analysis; while the second study included 15 studies, involving 18 cohorts. The results showed a modest but statistically significant inverse relationship between magnesium supplementation and the risk of stroke. This relation was observed with an increment of 100 mg per day of magnesium supplementation, which was associated with an 8% and 2% respective reduction in total stroke risk, especially ischemic strokes.
This two-stage, double-blind, placebo-controlled, randomized trial looked at the effects of magnesium and vitamin B6 supplementation on the severity of premenstrual syndrome (PMS) in patients during 2009 – 2010. This multicenter trial supplemented 126 women with either placebo or magnesium for 4 months. Participants were evaluated for PMS symptoms, including cravings, depression, anxiety, water retention, and somatic changes (feeling cold, nausea, frequent urination, back pain, headaches, joint, and muscle pain). The results show significant improvement in mean scores of PMS in all of the categories in the intervention group, compared to the placebo group.
A systematic review of clinical trials that evaluated the effects of magnesium supplementation on subjective anxiety and stress was published in 2017. This review included 18 clinical studies that recruited patients based on existing vulnerability to anxiety; mildly anxious, premenstrual syndrome (PMS), postpartum status, and hypertension. The results show a beneficial effect of Mg on subjective anxiety in anxiety vulnerable samples
In this randomized, positively controlled clinical trial, twenty-three elderly patients with type II diabetes and hypomagnesemia (defined by serum magnesium levels <1.8 mg/dL) were recruited to receive either magnesium (450 mg elemental) or 50 mg imipramine, a tricyclic antidepressant, per day for 12 weeks. The primary trial endpoint was the improvement of depression symptoms.
The results show an improvement in depressive symptoms in both groups, with no significant differences between the groups, leading the authors to conclude that magnesium supplementation could represent an effective option of therapy in depressed, elderly, type II diabetics with hypomagnesemia.
A cross-sectional, population-based data set (National Health and Nutrition Examination Survey) was used to explore the relationship of magnesium intake and depression in 8894 US adults (mean age, 46.1 years; 47.4% men) from 2007 to 2010. This was done to assess the existence of a relationship between magnesium intake and depression in adult populations.
The results showed that very low magnesium intake was sufficient to significantly improve depressive symptoms in older adults.
This study evaluating the status of magnesium, zinc, and copper status in post-menopausal women with osteoporosis, osteopenia, or normal bone mineral density (BMD) aimed to determine if the status of these minerals were associated with changes in bone health. 120 participants were included in the study, which showed that magnesium and zinc were significantly lower in osteoporotic women than in both osteopenic and normal BMD women. Additionally, the levels of magnesium and zinc were lower in the osteopenic women, compared to the normal BMD women. No difference in copper levels was observed between the groups, suggesting that magnesium and zinc deficiencies might be a contributing factor to bone loss in postmenopausal women.
In this study, age-matched, BMI-matched, and menopause duration-matched postmenopausal women were divided into two groups, to receive magnesium citrate at 1830 mg/day, corresponding to approximately 210 mg elemental magnesium per day or no medication. The participants were followed up with for 30 days, during which fasting blood and first-void urine samples were collected on days zero, one, five, 10, 20, and 30 respectively. The samples were measured for total magnesium, calcium, phosphorus, iPTH (parathyroid hormone), and osteocalcin in the blood and deoxypyridinoline levels, adjusted for creatinine were measured in the urine. Thirty consecutive days of oral magnesium supplementation caused a significant decrease in serum iPTH levels in the magnesium supplemented group; Serum osteocalcin levels were significantly increased and urinary deoxypyridinoline levels were decreased in the magnesium group, compared to the control group, suggesting that magnesium supplementation efficiently suppressed bone turnover in postmenopausal women.
In this perspective, placebo-controlled, randomized, one-year double-blind study, the role of magnesium supplementation as a determinant of bone mass was explored, in preadolescent girls. Over 120 participants, eight to 14 years, were given either placebo or 300 mg elemental magnesium for 12 months and assessed for bone mineral content of the total hip, femoral neck, Ward’s area, and lumbar spine after supplementation. The results show a significant increase in bone mineral content in the magnesium supplemented group, compared to the placebo. Trends for positive effects were evident in the pre-, early and mid-late puberty girls, suggesting the health benefits of oral magnesium supplementation in bone health of healthy adolescent girls.
In this prospective study and meta-analysis, the effects of magnesium and fiber intake on the risk of type II diabetes were evaluated. The prospective study included 9,702 men and 15,365 women, aged 35-65 years old, who were observed for incident diabetes from 1994-2005.
The authors observed 844 incident cases of type II diabetes in the European Prospective Investigation Into Cancer and Nutrition-Potsdam and meta-analysis showed an inverse relationship between fiber and magnesium intake and diabetes risk.
Another meta-analysis of prospective cohort studies included seven cohort studies, 286,668 participants, and 10,912 cases of type II diabetes. Participants supplemented with at least 100 mg increase in magnesium intake. The authors conclude that magnesium intake was inversely associated with the incidence of type II diabetes.
A more recent meta-analysis of prospective cohort studies, using a random-effects model and 13 prospective cohort studies, 536,318 participants and 24,516 cases of type II diabetes, came to the same conclusion, that magnesium supplementation was significantly inversely associated with the risk of type II diabetes.
A double-blind, placebo-controlled, randomized trial evaluated the effect of magnesium supplementation on insulin resistance in non-diabetic, overweight, insulin participants. Participants were randomized to receive either a placebo or magnesium aspartate for 6 months. At the trial endpoints, several indices of insulin sensitivity, plasma glucose, serum insulin, blood pressure, and lipid profile were determined.
Results show a significant improvement in fasting plasma glucose and insulin sensitivity indices in the magnesium supplementation group, compared to the placebo group.
A systematic review of 12 randomized, controlled clinical trials, free of restrictions with regards to age, sex, ethnicity, and differential dosing/shape of magnesium, aimed to demonstrate that magnesium had a role in insulin resistance, hyperglycemia, and hyperinsulinemia. The results from eight of the studies showed that magnesium supplementation influenced serum fasting glucose, while five trials demonstrated that magnesium supplementation reduced homeostasis model assessment for insulin resistance, providing evidence for magnesium supplementation in reducing IR in patients with hypomagnesemia presenting insulin resistance.
In this randomized, placebo-controlled, double-blind study, 89 children, with mild or moderate persistent bronchial asthma, were randomized to receive placebo or magnesium (from magnesium citrate (≤ seven-year-olds received 200 mg magnesium per day and > seven-year-olds received 290 mg magnesium per day) for 12 weeks. Each participant was evaluated at four-week intervals and bronchodilator rescue medications were used as needed.
Results show significantly higher use of bronchodilators in the placebo group, compared to magnesium supplemented group, leading the authors to conclude that “Long-lasting Mg supplementation is clearly of benefit in mildly to moderately asthmatic children and is recommended as a concomitant drug in stable asthma.”
Epidemiological evidence suggests that low magnesium intake may be related to the incidence and progression of asthma. This randomized, placebo-controlled wanted to determine if long-term oral magnesium supplementation could improve asthma control in adults with mild-to-moderate asthma. 55 participants were randomized to receive either a placebo or 170 mg elemental magnesium twice daily for six and a half months. The markers of asthma control were: methacholine challenge test(MCCT) and pulmonary function test(PFT) results, as well as validated questionnaires and markers of inflammation, were used to assess the efficacy.
The results show an improvement in the quality of symptoms and reduced bronchial reactivity in the magnesium-supplemented group.
The main objective of this double-blind, randomized, placebo-controlled trial was to determine the long-term effect of oral magnesium supplementation on clinical symptoms, bronchial reactivity, lung function, and allergen-induced skin responses in children and adolescents with moderate persistent asthma. 37 participants were randomized to receive either a placebo or 300 mg magnesium per day for two months. Both patient groups received inhaled fluticasone (250 micrograms twice a day) and salbutamol as needed.
Results show that magnesium supplementation was associated with a significant reduction in bronchial reactivity, fewer asthma exacerbation, better symptom control, and less need for rescue medication than the placebo group.
A systematic review of clinical evidence from 1990 to 2016 was conducted to systematically evaluate the existing evidence for magnesium supplementation as a migraine prophylaxis. This is based on research that shows that magnesium deficiency is associated with factors that promote headaches, including neurotransmitter release and vasoconstriction, and that people who experience migraines tend to have lower levels of serum magnesium, compared to those who do not. This publication included randomized, double-blind, placebo-controlled trials investigating prophylactic magnesium administration in migraineurs aged 18-65; 5 clinical trials were eligible according to the above trial. Results show a significant reduction in the number of migraine attacks in the migraine supplementation groups, compared with the placebos. Prophylactic benefit of magnesium supplementation was observed in a dose-dependent manner.
An evidence-based guideline published by the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society in 2012, looked at the available evidence for nonsteroidal anti-inflammatory drugs (NSAIDs) or complementary treatments for the prevention of episodic migraines in otherwise healthy adults. The authors analyzed publications over a 10-year period, which included 49 articles on migraine prevention, of which 15 articles were classified as involving non-traditional migraine therapies. Among the other treatments, magnesium supplementation was considered possibly effective for migraine prevention.
This study aimed to provide evidence for the use of magnesium in migraine prophylaxis in patients with two to five migraines per month, especially since at the time it was published, there were inconsistencies in the findings of magnesium use in migraines. 40 patients, without aura, were randomized to receive either a placebo or magnesium, at 600 mg per day for three months, in this double-blinded study.
Migraine attack frequency, severity, and P1 amplitude in visual evoked potential examination decreased after magnesium treatment, compared to the pretreatment values; post/pretreatment ratios of migraine attack frequency, severity, and P1 amplitude in Mg treatment group were found to be significantly lower than those in the placebo treatment group. Interestingly, magnesium supplementation increased cortical blood flow in the inferolateral frontal, temporal, and insular regions, suggesting the benefit of magnesium supplementation in patients suffering from migraines, without aura.